Abstracts tagged "pregnancy"

Abstract Number: 0722 • ACR Convergence 2023
Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies
Rashmi Dhital¹, Rebecca Baer², Monica Guma², Kenneth Kalunian², Accelerating Medicines Partnership Program RA SLE Network³ and Christina Chambers², ¹UC San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Cardiovascular diseases (CVDs) complicate 1-4% of pregnancies. Autoimmune rheumatic diseases (ARDs) are associated with a 1.5 to 3-fold higher CVD risk. Similarly, antiphospholipid syndrome…
Abstract Number: 1362 • ACR Convergence 2023
Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs
Rina Ferguson¹, Itay Marmor² and Maleewan Kitcharoensakkul¹, ¹Washington University/B-JH/SLCH Consortium, St. Louis, MO, ²Dana-Dwek Children's Hospital, Hod Hasharon, Israel
Background/Purpose: Several rheumatologic medications routinely prescribed to adolescent females are teratogenic. However, there is no standard method to educate our patients and their families about…
Abstract Number: 0194 • ACR Convergence 2023
Reproductive Health Conversations with a Primarily Hispanic Systemic Lupus Erythematosus Population: Influences and Barriers
Zarmeen Zaheer¹, Martha Delgado², Jack Rodman³, Julia Simard⁴, Sandy Lee⁵ and Leanna Wise⁶, ¹Huntington Health, Tampa, FL, ²LAC+USC/Keck School of Medicine, Los Angeles, CA, ³University of Southern California, Los Angeles, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵University of Southern California, Walnut, CA, ⁶LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease most commonly seen in women of childbearing age, with a greater burden in non-Caucasian populations. The…
Abstract Number: 0903 • ACR Convergence 2023
Effects of Hydroxychloroquine on Maternal Outcomes in Pregnant Patients with Systemic Lupus Erythematous
Yurilu Gonzalez¹ and Irene Tan², ¹Albert Einstein Medical Center, Wyncote, PA, ²Einstein Medical Center Philadelphia, Bala Cynwyd, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, that affects women of childbearing age. SLE is a high-risk condition in pregnant patients due…
Abstract Number: 1364 • ACR Convergence 2023
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴, Rebecca Jacobson¹ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: We evaluated the role of maternal 25(OH)-vitamin D in adverse pregnancy outcomes in systemic lupus erythematosus (SLE). Methods: We used a longitudinal cohort that…
Abstract Number: 0463 • ACR Convergence 2023
Appropriate Preconception Care Improves Pregnancy Outcomes in SLE Patients
Hiromi Shimada¹, Rina Mino², Risa Wakiya³, Shusaku Nakashima³, Taichi Miyagi⁴, Yusuke Ushio⁵, Koichi Sugihara⁶, Mao Mizusaki³, Kanako Chujo⁷, Ryoko Kagawa⁵, Hayamasa Yamaguchi⁵, Tomohiro Kameda³ and Hiroaki Dobashi³, ¹Kagawa University, Kagawa, Japan, ²Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁵Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁶Kagawa University, Miki-cho, Kita-gun, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: Pregnancies complicated by systemic lupus erythematosus (SLE) are known to be at high risk for adverse pregnancy outcomes (APOs). Previous studies have shown that…
Abstract Number: 0979 • ACR Convergence 2023
Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St. Pierre², Olga Basso¹, Anick Bérard⁴ and Evelyne Vinet⁵, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…
Abstract Number: 1571 • ACR Convergence 2023
Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis
Nurul Aulia Zakaria¹, Andrew Porter², Robert Maughan², Charis Pericleous², Japna Satara³, Matthew Colquhoun⁴, Priyanka Agrawal³, jan Nouza³, Harold Wilson-Morkeh³, Taryn Youngstein² and Justin Mason², ¹National Heart & Lung Institute, Imperial College London, Kuantan, Malaysia, ²National Heart & Lung Institute, Imperial College London, London, United Kingdom, ³Rheumatology, Hammersmith Hospital, London, United Kingdom, ⁴Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…
Abstract Number: 0464 • ACR Convergence 2023
Adverse Pregnancy Outcomes in Sjogren’s Disease Compared to Controls: An Interdisciplinary Approach with Maternal Fetal Medicine
Lauren Tesoriero¹, Jennifer Kidd¹, Julie Piccione¹, Izmirly peter², Meredith Akerman¹, Steven Carsons¹, Patricia Rekawek¹ and Julie Nusbaum¹, ¹NYU Long Island School of Medicine, Mineola, NY, ²NYU, New York, NY
Background/Purpose: Outside of the known association of Ro antibody with congenital heart block (CHB), little is known about adverse maternal outcomes, and even less about…
Abstract Number: 0986 • ACR Convergence 2023
Medication Use Patterns and Factors Associated with Abnormal Pregnancy Outcomes in Patients with Rheumatoid Arthritis in Korea
Yeo-Jin Song¹, Soo-Kyung Cho¹, Yu-Seon Jung², Jihyun Keum³, Sun-Young Jung², Dae Hyun Yoo⁴ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²College of Pharmacy, Chung-Ang University, Seoul, South Korea, ³Department of Obstetrics and Gynecology, College of Medicine, Hanyang University, Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: As female patients constitute a significant proportion of rheumatoid arthritis (RA) cases, pregnancy management is crucial for women with RA. This study aimed to…
Abstract Number: 1681 • ACR Convergence 2023
Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Eri Soga², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Tama, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Tacrolimus is one of the major treatment options of systemic lupus erythematosus (SLE) and is thought to be pregnancy compatible medication. Since little is…
Abstract Number: L13 • ACR Convergence 2022
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
Stephanie Benjamin¹, Lisa Vi², Diptendu Chatterjee¹, Edgar Jaeggi¹, Marie Wahren-Herlenius³, Amelia Ruffatti⁴, Linda Hiraki⁵, Michelle Lohbihler², Lusia Sepiashvili¹, Carl Laskin⁶, Meena Fatah¹, Daniela Dominguez⁵, Lawrence Ng⁵, Anthony Gramolini², Vincent Christoffels⁷, Stephanie Protze² and Robert Hamilton⁸, ¹Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ⁴Universitå di Padova, Padova, Italy, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁷Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, ⁸Hospital for Sick Children, Markham, ON, Canada
Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
Abstract Number: 0955 • ACR Convergence 2022
Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort
SABRINA HAMROUN¹, Marion Couderc², Rene-Marc Flipo³, Laure Gossec⁴, Christophe Richez⁵, Rakiba Belkhir⁶, Aline Frazier-Mironer⁷, Valerie Devauchelle⁸, Hubert Marotte⁹, Jérémie SELLAM¹⁰, elisabeth gervais¹¹, Alban DEROUX¹², Cédric Lukas¹³, Emmanuelle Dernis¹⁴, Emmanuel Chatelus¹⁵ and Anna Molto¹⁶, ¹Rheumatology Department, University Hospital of Cochin, Paris, Paris, France, ²University Hospital, Clermont-Ferrand, France, ³CHU Lille, Boulogne-Billancourt, France, ⁴Sorbonne Université, Paris, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁷APHP Hôpital Lariboisire, Paris, France, ⁸Université de Bretagne Occidentale, Brest, France, ⁹INSERM 1059, Saint-Etienne, France, ¹⁰Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ¹¹chu poitiers, Poitiers, France, ¹²CHU Grenoble, Grenoble, France, ¹³University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ¹⁴LE MANS general hospital, LE MANS, France, ¹⁵University Hospital of Strasbourg, Strasbourg, France, ¹⁶Rheumatology Department, Cochin Hospital, APHP, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge…
Abstract Number: 1672 • ACR Convergence 2022
The Impact of Systemic Sclerosis (SSc) on Women’s Health Evaluated with a New SSc-specific Patient-reported Questionnaire
Maria Grazia Lazzaroni¹, Liala Moschetti¹, Eleonora Pedretti¹, Andrea Lojacono², Francesca Ramazzotto³, Cristina Zanardini³, Zatti Sonia³, Angela Tincani⁴, Franco Franceschini¹, Paolo Airò⁵ and Laura Andreoli¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Obstetrics and Gynecology, ASST Garda, Desenzano del Garda, Brescia, Brescia, Italy, ³Obstetrics and Gynecology, ASST Spedali Civili and University of Brescia, Brescia, Italy, ⁴Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy, ⁵Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy
Background/Purpose: Systemic Sclerosis (SSc) has a strong female predominance and can significantly impair the everyday quality of life of patients. We aimed at designing a…
Abstract Number: 0956 • ACR Convergence 2022
Contribution of Antibody Titers/Specificities to Adverse Pregnancy Outcomes in a Multicenter Prospective Study of anti-Ro Positive Mothers
Nicola Fraser¹, Mala Masson², Kristina Deonaraine³, Philip Carlucci⁴, Colin Phoon⁵, Ashley Roman⁵, Peter Izmirly⁶, Amit Saxena⁵, Michael Belmont⁶, Christina Penfield⁵, Young Mi Lee⁵, Julie Nusbaum⁷, Bruce Solitar⁵, Fardina Malik⁵, Paula Rackoff¹, Rebecca Haberman¹, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Albuhamad⁹, Majd Makhoul¹⁰, Gary Satou¹¹, Nelangi Pinto¹², Anita Moon-Grady¹³, Lisa Howley¹⁴, Stephanie Levasseur¹⁵, Jyothi Matta¹⁶, Christopher Lindblade¹⁷, Andrew Rubenstein¹⁸, Caitlin Haxel¹⁹, Katherine Kohari²⁰, Joshua Copel²⁰, James Strainic²¹, Tam Doan²², Karla Bermudez-Wagner²², Shreya Sunil Sheth²², Stacy Killen²³, Theresa Tacy²⁴, Michelle Kaplinski²⁴, Bailey Drewes²⁵, Robert Clancy⁶, Bettina Cuneo²⁶ and Jill Buyon⁶, ¹NYU School of Medicine, New York, NY, ²NYU Langone Medical Center- Division of Rheumatology, New York, NY, ³University at Buffalo, Buffalo, NY, ⁴NYU Langone, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷NYU Long Island School of Medicine, Mineola, NY, ⁸Children's Heart Center, Las Vegas, ⁹East Virginia Medical School, Norfolk, VA, ¹⁰University of Kentucky, Lexington, KY, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Utah, Salt Lake City, ¹³UCSF, San Francisco, ¹⁴Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁵Columbia University, New York, NY, ¹⁶University of Louisville, Louisville, KY, ¹⁷Phoenix Children's Hospital, Phoenix, ¹⁸Dignity Health, Phoenix, ¹⁹University of Vermont Children's Hospital, Burlington, VT, ²⁰Yale University, New Haven, CT, ²¹UH Rainbow Babies, Cleveland, OH, ²²Baylor College of Medicine, Houston, TX, ²³Vanderbilt University, Nashville, TN, ²⁴Stanford University, Stanford, CA, ²⁵University of Colorado, Denver, CO, ²⁶University of Colorado School of Medicine, Aurora, CO
Background/Purpose: While it is well accepted that congenital heart block (CHB) and neonatal annular rash are highly associated with maternal anti-Ro60 and 52 autoantibodies, the…

« Previous Page
1
…
5
6
7
8
9
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].